
|Articles|January 27, 2021
Supplements and Featured Publications
- The Role of Lipoprotein(a) As a Biomarker to Assess Cardiovascular Risk
The Role of Lipoprotein(a) As a Biomarker to Assess Cardiovascular Risk
Advertisement
This publication is sponsored by Novartis AG.
This Clinical Practice Brief provides an overview of the genetic cardiovascular risk biomarker lipoprotein a (Lp[a]), as well as its importance as an independent risk factor for cardiovascular disease, the prevalence of elevated Lp(a) levels among the global population, and recommendations for lipid management.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
NIH Grant Terminations Disrupt 1 in 30 Clinical Trials, Impacting Over 74,000 Participants
2
Guselkumab Shows Sustained 48-Week Protection Against Joint Damage in PsA
3
Clinician Shortages, Access Gaps Challenge Rural Primary Care
4
Medicaid Pays for Half of All Pediatric Hospitalizations
5















































